Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

Introduction: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. Methods: We reviewed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Whitney E. Lewis, PharmD, Lingzhi Hong, MD, PhD, Frank E. Mott, MD, George Simon, MD, Carol C. Wu, MD, Waree Rinsurongkawong, MS, MS, PhD, J. Jack Lee, MS, PhD, Vincent K. Lam, MD, John V. Heymach, MD, PhD, Jianjun Zhang, MD, PhD, Xiuning Le, MD, PhD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Lung squamous cell carcinoma Targeted therapy Tyrosine kinase inhibitor EGFR ALK Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2660592405ef472eb275c6fe7d53fee6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2660592405ef472eb275c6fe7d53fee6
record_format	dspace
spelling	oai:doaj.org-article:2660592405ef472eb275c6fe7d53fee62021-12-02T05:03:46ZEfficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations2666-364310.1016/j.jtocrr.2021.100237https://doaj.org/article/2660592405ef472eb275c6fe7d53fee62021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666364321000965https://doaj.org/toc/2666-3643Introduction: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. Methods: We reviewed the database of the MD Anderson Cancer Center and identified metastatic LUSC with classic EGFR or ALK alterations. Results: There were eight patients with EGFR-mutant LUSC (median age = 58 y) and six patients with EML4-ALK LUSC (median age = 50 y) who received tyrosine kinase inhibitors (TKIs) that were identified. Of the 14 patients, 11 (79%) were females and 12 (86%) were never smokers, similar to the demographics of EGFR or ALK LUAD. With TKI treatment, seven of eight cases of EGFR LUSC and four of six cases of ALK LUSC achieved partial response or stable disease, but the progression-free survival was 4.9 months and 2.9 months for EGFR-mutant and ALK-rearranged LUSC, respectively. In addition, we compared comutation profile of EGFR-mutant LUAD (The Cancer Genome Atlas, n = 46) versus LUSC (n = 19) and found that the comutation patterns are more consistent with squamous disease with a higher incidence of PIK3CA (p = 0.02) and KRAS or BRAF (p = 0.04) alterations. Conclusions: EGFR or ALK alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD.Whitney E. Lewis, PharmDLingzhi Hong, MD, PhDFrank E. Mott, MDGeorge Simon, MDCarol C. Wu, MDWaree Rinsurongkawong, MS, MS, PhDJ. Jack Lee, MS, PhDVincent K. Lam, MDJohn V. Heymach, MD, PhDJianjun Zhang, MD, PhDXiuning Le, MD, PhDElsevierarticleLung squamous cell carcinomaTargeted therapyTyrosine kinase inhibitorEGFRALKNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100237- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lung squamous cell carcinoma Targeted therapy Tyrosine kinase inhibitor EGFR ALK Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Lung squamous cell carcinoma Targeted therapy Tyrosine kinase inhibitor EGFR ALK Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Whitney E. Lewis, PharmD Lingzhi Hong, MD, PhD Frank E. Mott, MD George Simon, MD Carol C. Wu, MD Waree Rinsurongkawong, MS, MS, PhD J. Jack Lee, MS, PhD Vincent K. Lam, MD John V. Heymach, MD, PhD Jianjun Zhang, MD, PhD Xiuning Le, MD, PhD Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
description	Introduction: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. Methods: We reviewed the database of the MD Anderson Cancer Center and identified metastatic LUSC with classic EGFR or ALK alterations. Results: There were eight patients with EGFR-mutant LUSC (median age = 58 y) and six patients with EML4-ALK LUSC (median age = 50 y) who received tyrosine kinase inhibitors (TKIs) that were identified. Of the 14 patients, 11 (79%) were females and 12 (86%) were never smokers, similar to the demographics of EGFR or ALK LUAD. With TKI treatment, seven of eight cases of EGFR LUSC and four of six cases of ALK LUSC achieved partial response or stable disease, but the progression-free survival was 4.9 months and 2.9 months for EGFR-mutant and ALK-rearranged LUSC, respectively. In addition, we compared comutation profile of EGFR-mutant LUAD (The Cancer Genome Atlas, n = 46) versus LUSC (n = 19) and found that the comutation patterns are more consistent with squamous disease with a higher incidence of PIK3CA (p = 0.02) and KRAS or BRAF (p = 0.04) alterations. Conclusions: EGFR or ALK alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD.
format	article
author	Whitney E. Lewis, PharmD Lingzhi Hong, MD, PhD Frank E. Mott, MD George Simon, MD Carol C. Wu, MD Waree Rinsurongkawong, MS, MS, PhD J. Jack Lee, MS, PhD Vincent K. Lam, MD John V. Heymach, MD, PhD Jianjun Zhang, MD, PhD Xiuning Le, MD, PhD
author_facet	Whitney E. Lewis, PharmD Lingzhi Hong, MD, PhD Frank E. Mott, MD George Simon, MD Carol C. Wu, MD Waree Rinsurongkawong, MS, MS, PhD J. Jack Lee, MS, PhD Vincent K. Lam, MD John V. Heymach, MD, PhD Jianjun Zhang, MD, PhD Xiuning Le, MD, PhD
author_sort	Whitney E. Lewis, PharmD
title	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_short	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_full	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_fullStr	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_full_unstemmed	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_sort	efficacy of targeted inhibitors in metastatic lung squamous cell carcinoma with egfr or alk alterations
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/2660592405ef472eb275c6fe7d53fee6
work_keys_str_mv	AT whitneyelewispharmd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT lingzhihongmdphd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT frankemottmd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT georgesimonmd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT carolcwumd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT wareerinsurongkawongmsmsphd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT jjackleemsphd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT vincentklammd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT johnvheymachmdphd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT jianjunzhangmdphd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations AT xiuninglemdphd efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
_version_	1718400638361010176

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

Ejemplares similares